Navigation Links
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
Date:7/9/2008

-- Dr. Fernando Perez-Ruiz Joins Ardea's Inflammatory Disease Scientific

Advisory Board --

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has received regulatory approval to begin a Phase 2a proof-of-concept clinical trial evaluating RDEA806 in gout patients with hyperuricemia. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream, and is the most common form of inflammatory arthritis in men over 40. The Company also announced that gout specialist, Dr. Fernando Perez-Ruiz in Spain, will be the newest member of its inflammatory disease scientific advisory board (SAB).

Ardea previously announced the designation of RDEA594, a major metabolite of RDEA806, the Company's lead human immunodeficiency virus (HIV) development compound, as its lead development candidate for the treatment of patients with gout. RDEA594 does not have antiviral activity, but is believed to be responsible for essentially all of the uric acid lowering effects seen with RDEA806. Uric acid lowering effects have been observed following administration of RDEA806 in Phase 1 and Phase 2 clinical trials that included over 100 subjects.

"The Phase 2a trial should allow us to confirm RDEA594's activity in the target population of patients with gout using its prodrug, RDEA806. Enrollment in the Phase 2a trial should begin shortly and we are on track to initiate a Phase 1 trial with RDEA594 in the second half of this year," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "We also are extremely pleased to add Dr. Fernando Perez-Ruiz to our inflammatory diseases S
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Craig Johnson Joins Ardea Biosciences Board of Directors
2. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
3. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
4. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
5. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
6. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
7. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
8. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
9. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
10. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
11. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... CALGARY , June 30, 2015 /PRNewswire/ - ... ("Shareholders") of common shares of Resverlogix have approved ... to Eastern Capital Limited of 5,600,000 units at ... Private Placement"), each unit being comprised of one ... for aggregate proceeds of approximately CAD$15 million; and ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Library of Life Science Research and Enables Experiment ... SIAL ) and Ingenuity Systems today ... Web-based biological search portal for exploring dynamic gene-based ... extensive library of research findings, Your Favorite Gene ...
... Development of Accurate Blood Test for Common Genetic Disorders ... Artemis Health Inc., a privately-held company dedicated to the ... it has acquired a co-exclusive worldwide license from ... diagnostic tests based on pioneering research from the lab ...
... Australia, Jan. 27 /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS,Nasdaq: ... Quarterly Report to Shareholders,on the afternoon of Wednesday, 28th ... teleconference the following morning to review the quarter,and answer ... will be on Thursday, 29th January at 8:30am (Sydney),(Wednesday, ...
Cached Biology Technology:Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity 2Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity 3Sigma-Aldrich Launches Your Favorite Gene Powered by Ingenuity 4Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 2Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University 3
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
(Date:6/16/2015)... 2015 Fingerprint Cards has received an ... the company,s portfolio from one of its module partners in ... take place during the third quarter 2015. The sensors will ... . Jörgen Lantto, CEO of FPC, comments: " ... growing interest from smartphone OEMs in integrating touch fingerprint sensors ...
(Date:6/15/2015)... A new report [ 1 ] ... consumers using mobile banking applications want their mobile devices to ... instead of having to prove who they are with passwords ...   -   The Fusion of Financial Services, Mobile and ... channel used by Gen X and Gen Y to access ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... diet high in red meat, fatty products, refined grains, ... be increasing their chance of disease relapse and early ... study, published in the Aug. 15 issue of the ... with stage III colon cancer that has been treated ...
... show it is overwhelmingly likely that life began ... scientists. Professor Chandra Wickramasinghe and colleagues at ... case for panspermia - the theory that life ... across the galaxy. A recent BBC Horizon documentary ...
... torrents of microscopic waves propel white blood cells toward ... holds the potential for better understanding and treatment of ... very high-resolution light microscope, the dynamic waves are made ... protein and a second key player were already known ...
Cached Biology News:'Western' diet linked to increased risk of colon cancer recurrence 2Bursts of waves drive immune system 'soldiers' toward invaders 2Bursts of waves drive immune system 'soldiers' toward invaders 3Bursts of waves drive immune system 'soldiers' toward invaders 4
Goat polyclonal to DRAK2...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... contain a proprietary high-performance desalting resin, exclusive ... protein-recovery characteristics compared to other commercially available ... g/ml of protein can be processed, providing ... of salts and other small molecules ( ...
... This immunoaffinity purified antibody detects an ... molecular mass of ErbB-2 phosphorylated at tyrosine ... product has been cross adsorbed against the ... detect the non-phosphorylated form of the protein. ...
Biology Products: